Quratis Inc

Quratis Inc has a liquidity position characterized by a current ratio of 1.23, indicating that its current assets slightly exceed its current liabilities. The company holds cash and equivalents of KRW 9,390,477,230, but this is offset by long-term debt of KRW 9,539,711,180, resulting in a net cash position that is negative after subtracting total debt. The company's free cash flow is negative at KRW -29,380,668,850, reflecting significant outflows from operations and capital expenditures. Profitability metrics for Quratis Inc are negative, with a return on equity of -0.6704 and a return on assets of -0.5422. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at KRW -11,452,042,250, and the net income is KRW -29,672,988,850, which is significantly below the industry median for pharmaceutical companies. The company's revenue is concentrated in its core biopharmaceuticals and CPP platform services, with no disclosed geographic diversification in the financial snapshot. This lack of geographic segmentation suggests that the company's revenue is primarily derived from its domestic market in Korea. The absence of international revenue exposure may limit growth opportunities and increase vulnerability to local economic conditions. Quratis Inc's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's historical financial performance shows a consistent pattern of negative operating and net income, which may indicate challenges in scaling operations or achieving profitability. The capital expenditure of KRW -4,112,400,000 suggests ongoing investment in infrastructure, but the negative free cash flow indicates that these investments are not yet generating positive returns. The risk assessment for Quratis Inc highlights medium liquidity risk and low dilution potential. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in meeting short-term obligations. The low dilution potential suggests that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders. Recent events and filings for Quratis Inc are not detailed in the provided data, but the company's ongoing losses and negative cash flows suggest that it may be focusing on research and development activities rather than immediate profitability. The company's engagement in the development of vaccines, such as tuberculosis vaccines for adults and adolescents, and COVID-19 vaccines, indicates a strategic focus on long-term product pipelines.